Live In Play

Live In Play®

Updated: 05-Sep-23 06:06 ET

FATE: Fate Therapeutics issued an update on its litigation proceedings against Shoreline Biosciences (2.81)

State Case Update: Litigation in the State Case is pending, and fact and expert discovery is ongoing. A trial in San Diego Superior Court has been scheduled for January 2024.
Federal Case Update: The Federal Case alleged infringement of certain U.S. patents expiring in November 2024, which are exclusively licensed to the Company by Whitehead Institute for Biomedical Research (the "Whitehead Patents"). The Whitehead Patents include certain composition of matter patents, including U.S. Patent No. 8,071,369 issued on December 6, 2011, as well as certain method of use patents relating to methods of making a somatic cell more susceptible to reprogramming to a pluripotent state by introducing at least one exogenous nucleic acid encoding Oct 4. On August 28, 2023, the Court conducted a hearing to consider the parties' cross-motions for summary judgment. Shoreline represented throughout the case that it does not itself reprogram somatic cells or manufacture iPSCs, and that its therapeutic business is founded on the purchase and use of iPSC lines from third parties, including primarily an iPSC line that Shoreline claims was originally manufactured by Lonza almost 10 years ago for the National Institute of Health (NIH) and made generally available to the research community. On August 30, 2023, the Court granted Shoreline's motion for summary judgment of non-infringement and denied the Company's, ruling that Shoreline did not infringe the Whitehead Patents through its purchase and use of the third-party iPSC lines. The Company strongly disagrees with the Court's ruling.